Hao-Yuan Chuang Sells 17,962 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CFO Hao-Yuan Chuang sold 17,962 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $196.42, for a total transaction of $3,528,096.04. Following the transaction, the chief financial officer directly owned 26,038 shares in the company, valued at approximately $5,114,383.96. The trade was a 40.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Hao-Yuan Chuang also recently made the following trade(s):

• On Friday, September 4th, Hao-Yuan Chuang sold 49,433 shares of Belite Bio stock. The stock was sold at an average price of $187.64, for a total transaction of $9,275,608.12.
• On Wednesday, August 12th, Hao-Yuan Chuang sold 367 shares of Belite Bio stock. The stock was sold at an average price of $180.35, for a total transaction of $66,188.45.

Belite Bio Price Performance

Shares of NASDAQ BLTE opened at $175.07 on Friday. Belite Bio, Inc. Sponsored ADR has a 1 year low of $64.80 and a 1 year high of $200.00. The company’s 50-day moving average is $161.12 and its 200 day moving average is $158.68. The stock has a market capitalization of $7.05 billion, a P/E ratio of -64.13 and a beta of -1.23.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share (EPS) for the quarter. Research analysts anticipate that Belite Bio, Inc. Sponsored ADR will post -3.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BLTE. Mizuho lifted their price target on Belite Bio from $220.00 to $234.00 and gave the company an “outperform” rating in a research report on Wednesday. Benchmark reiterated a “buy” rating on shares of Belite Bio in a report on Friday, August 14th. Jefferies Financial Group reissued a “hold” rating on shares of Belite Bio in a research report on Wednesday. UBS Group restated a “buy” rating on shares of Belite Bio in a report on Thursday, September 3rd. Finally, Zacks Research lowered shares of Belite Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 18th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $218.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Darwin Global Management Ltd. bought a new stake in Belite Bio in the fourth quarter worth $486,915,000. RA Capital Management L.P. bought a new position in shares of Belite Bio during the third quarter valued at $64,750,000. Millennium Management LLC raised its position in shares of Belite Bio by 2,594.6% in the 4th quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock worth $89,399,000 after purchasing an additional 538,141 shares during the last quarter. RTW Investments LP raised its position in shares of Belite Bio by 128.9% in the 4th quarter. RTW Investments LP now owns 715,332 shares of the company’s stock worth $114,425,000 after purchasing an additional 402,832 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its stake in Belite Bio by 732.0% in the 4th quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock worth $66,262,000 after purchasing an additional 364,451 shares in the last quarter. Institutional investors own 0.53% of the company’s stock.

Key Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Belite Bio submitted a New Drug Application in Japan for tinlarebant, its once-daily oral treatment candidate for Stargardt disease type 1. The filing under Japan’s Sakigake designation could support expedited review, while the lack of approved treatments may enhance the drug’s commercial opportunity. Belite Bio Japan NDA announcement
• Positive Sentiment: Analyst sentiment remains generally constructive. Mizuho raised its price target to $234, Cantor Fitzgerald set a $270 target, and the analyst consensus is a “Moderate Buy” rating with an average target of $218.73. A Seeking Alpha analysis also highlighted the potential for a blockbuster launch in 2027. Belite Bio 2027 launch analysis
• Positive Sentiment: BLTE’s 50-day moving average recently moved above its 200-day moving average, forming a bullish “golden cross” that could attract technical and momentum-oriented investors. Belite Bio golden cross analysis
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling pressure based on the available data. However, the reported percentage change was unavailable.
• Negative Sentiment: Executives disclosed sizable stock sales. CFO Hao-Yuan Chuang sold approximately $12.8 million of shares across September 4 and September 8, reducing his holdings by roughly 41% in the latest transaction. CEO Yu-Hsin Lin sold approximately $19.1 million across the same dates, cutting ownership by about 28% and 44% in the respective transactions. The sales may concern investors because they occurred near the stock’s recent highs. Belite Bio insider selling report

About Belite Bio

Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases. The company’s research centers on therapies designed to address the underlying biological processes that contribute to vision loss, including the accumulation of toxic vitamin A–derived compounds in the retina.

Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. Tinlarebant is an orally administered retinol-binding protein 4 antagonist intended to reduce the delivery of vitamin A to the retina and limit the formation of toxic bisretinoids.